Penyakit
Leukaemia
ICD-10: C91–C95 — Leukaemia
Angka utama
Hanya nilai yang diterbitkan. Setiap ubin membuka bagian yang memuat sumber, tahun, dan kalibernya.
- Kisaran biaya pengobatan 25 kisaran yang diterbitkan, masing-masing dengan sumbernya di halaman baris
- Kelangsungan hidup lima tahun 30.6% 95% CI 30.2–31.1 · 2019–2021
- Rumah sakit dengan catatan yang diterbitkan 8 untuk penyakit ini, masing-masing dengan sumber yang diterbitkan
- Uji klinis 150 sedang merekrut atau belum merekrut, sebagaimana diterbitkan
Rincian penyakit
- Nama Inggris
- Leukaemia
Juga dikenal sebagai
- Leukaemia
- Leukemia
Kisaran biaya pengobatan
Setiap kisaran di bawah diterbitkan pada satu dasar penagihan: Sebelum penggantian asuransi. Sumber tidak menerbitkan angka setelah penggantian, jadi tidak ada yang ditampilkan di sini.
| Jalur pengobatan | Kisaran biaya | Dasar harga | Tahun data |
|---|---|---|---|
| Kemoterapi | 20000 – 20000 CNY | Harga paket per penyakit | 2020 |
| Kemoterapi | 54000 – 54000 CNY | Harga paket per penyakit | 2020 |
| Kemoterapi | 95000 – 95000 CNY | Harga paket per penyakit | 2020 |
| Kemoterapi | 87000 – 87000 CNY | Harga paket per penyakit | 2020 |
| Kemoterapi | 100000 – 100000 CNY | Harga paket per penyakit | 2020 |
| Kemoterapi | 7000 – 7000 CNY | Harga paket per penyakit | 2020 |
| Kemoterapi | 9000 – 9000 CNY | Harga paket per penyakit | 2020 |
| Kemoterapi | 36000 – 36000 CNY | Harga paket per penyakit | 2020 |
| Kemoterapi | 10500 – 10500 CNY | Harga paket per penyakit | 2020 |
| Kemoterapi | 42200 – 42200 CNY | Harga paket per penyakit | 2020 |
| Kemoterapi | 52700 – 52700 CNY | Harga paket per penyakit | 2020 |
| Kemoterapi | 95000 – 95000 CNY | Harga paket per penyakit | 2020 |
| Kemoterapi | 70800 – 70800 CNY | Harga paket per penyakit | 2020 |
| Kemoterapi | 28000 – 28000 CNY | Harga paket per penyakit | 2020 |
| Kemoterapi | 11500 – 11500 CNY | Harga paket per penyakit | 2020 |
| Kemoterapi | 66300 – 66300 CNY | Harga paket per penyakit | 2020 |
| Kemoterapi | 20800 – 20800 CNY | Harga paket per penyakit | 2020 |
| Kemoterapi | 36500 – 36500 CNY | Harga paket per penyakit | 2020 |
| Kemoterapi | 30100 – 30100 CNY | Harga paket per penyakit | 2020 |
| Kemoterapi | 50000 – 50000 CNY | Harga paket per penyakit | 2020 |
| Kemoterapi | 72000 – 72000 CNY | Harga paket per penyakit | 2020 |
| Kemoterapi | 30800 – 30800 CNY | Harga paket per penyakit | 2020 |
| Kemoterapi | 43300 – 43300 CNY | Harga paket per penyakit | 2020 |
| Kemoterapi | 72000 – 72000 CNY | Harga paket per penyakit | 2020 |
| Kemoterapi | 95400 – 95400 CNY | Harga paket per penyakit | 2020 |
Batang-batang berbagi satu skala di seluruh baris di atas: masing-masing dimulai dari angka terbit terendah baris itu dan berakhir pada angka tertingginya. Angka tertinggi di halaman ini adalah 100000 CNY. Setiap baris mempertahankan tahun data dan kalibernya sendiri.
25 kisaran biaya untuk penyakit ini, dengan sumbernya di halaman baris.
Nilai yang ditulis dalam bahasa Tiongkok dikutip sebagaimana diterbitkan oleh sumber.
Kelangsungan hidup lima tahun
Tingkat kelangsungan hidup 5 tahun 30.6% IK 95% 30.2–31.1
- Populasi
- Keseluruhan (semua stadium digabung) · Tingkat kelangsungan hidup relatif terstandar usia
- Periode
- 2019–2021
- Penerbit
- Pusat Kanker Nasional Tiongkok
- Sifat nilai
- Nilai estimasi (analisis campuran)
- Cakupan registri
- 281 registri kanker berbasis populasi
- Ketersediaan data stadium
- Tidak diterbitkan
Nilai yang ditulis dalam bahasa Tiongkok dikutip sebagaimana diterbitkan oleh sumber.
Cara membaca angka ini. Angka ini diterbitkan untuk semua stadium digabung, jadi ini rata-rata atas semua orang dalam data registri nasional, bukan prognosis untuk satu orang. Pada sebagian besar kanker, stadium saat diagnosis adalah faktor tunggal terkuat di balik perbedaan kelangsungan hidup: kelangsungan hidup umumnya lebih tinggi bila kanker ditemukan pada stadium lebih dini dan lebih rendah bila ditemukan lebih lambat. Perbandingan antar kanker juga dipengaruhi oleh seberapa dini atau lambat masing-masing cenderung didiagnosis, jadi angka yang lebih rendah tidak dengan sendirinya berarti mutu layanan yang lebih buruk.
Angka itu adalah kelangsungan hidup relatif: angka ini membandingkan orang yang didiagnosis kanker ini dengan orang seusia dan sejenis kelamin dalam populasi umum, dan distandardisasi menurut umur, jadi bukan proporsi pasien yang masih hidup setelah lima tahun. Angka ini diterbitkan sebagai nilai perkiraan (analisis hibrida) karena laporan registri datang dengan jeda, sehingga National Cancer Center memodelkan periode terakhir. Sebagai konteks, sumber yang sama menerbitkan kelangsungan hidup relatif lima tahun 43,7% untuk semua kanker gabungan pada 2019–2021.
Rumah sakit dengan catatan terbit untuk penyakit ini
Dipilih menggunakan sumber data publik resmi
Rumah sakit ini dipilih dari sumber data publik resmi — peringkat reputasi spesialisasi rumah sakit Universitas Fudan, daftar spesialisasi klinis kunci nasional, dan pusat riset klinis nasional — sehingga setiap baris pada kartu dapat diperiksa terhadap sumber terbitnya. Ini bukan daftar berbayar atau promosi.
Bagaimana rumah sakit ini dipilih
Penerimaan. Sebuah rumah sakit dicantumkan untuk suatu penyakit bila spesialisasi tempat penyakit itu dikelompokkan memuat paling sedikit satu dari: posisi atau nominasi dalam peringkat reputasi spesialisasi rumah sakit Universitas Fudan; catatan spesialisasi klinis kunci nasional pada tingkat A, B, atau C; atau pusat riset klinis nasional atau laboratorium kunci negara pada spesialisasi itu. Akreditasi JCI ditampilkan sebagai lencana; akreditasi itu tidak pernah menentukan penerimaan dan tidak pernah menentukan urutan.
Urutan. Langkah 1: posisi Fudan antara 1 dan 10 untuk spesialisasi itu. Langkah 2: posisi Fudan lain, atau nominasi. Langkah 3: spesialisasi klinis kunci nasional tingkat A. Langkah 4: spesialisasi klinis kunci nasional tingkat B. Langkah 5: pusat riset klinis nasional atau laboratorium kunci negara pada spesialisasi itu, pusat sebelum laboratorium. Langkah 6: spesialisasi klinis kunci nasional tingkat C, yaitu catatan yang kami terbitkan tanpa sumber resmi independen sehingga dicantumkan setelah yang lain.
Seri. Dalam satu langkah: posisi Fudan yang lebih baik lebih dahulu, lalu tingkat spesialisasi kunci yang lebih kuat (A sebelum B sebelum C), lalu provinsi, lalu kota, lalu nama rumah sakit - urutan provinsi-kota-nama yang sama seperti yang dipakai direktori rumah sakit. Paling banyak delapan rumah sakit dicantumkan.
Bila daftar pendek. Lima rumah sakit atau lebih: delapan yang pertama dicantumkan. Tiga atau empat: semuanya dicantumkan, dan satu lipatan tambahan menambahkan catatan sisanya sampai delapan, masing-masing membawa tingkat buktinya. Satu atau dua: sama, dengan lipatan itu terbuka dan satu baris yang menyatakan berapa rumah sakit yang memiliki catatan publik kuat. Tidak ada: halaman menyatakan bahwa tidak ditemukan catatan publik kuat dan menautkan ke direktori spesialisasi. Posisi, lembaga, atau jumlah tidak pernah diciptakan untuk mengisi daftar.
Peringkat Fudan adalah peringkat reputasi spesialisasi rumah sakit yang paling luas diakui oleh dokter Tiongkok, diterbitkan setiap tahun oleh institut manajemen rumah sakit Universitas Fudan.
-
West China Hospital, Sichuan University
Spesialisasi klinis kunci nasional
- Hematologi (tingkat A) https://wcums.scu.edu.cn/kxyan_jiu/gjlczdzk.htm
Juga diperingkat: Bedah Umum #3, Bedah Toraks #4, Urologi #2 (seri) dalam daftar Fudan.
-
Qilu Hospital of Shandong University
Spesialisasi klinis kunci nasional
- Hematologi (tingkat A) http://wsjkw.shandong.gov.cn/wmfw/cxfw/202307/P020230717441794577839.xlsx
Juga diperingkat: Ginekologi #7 (seri), Otolaringologi dinominasikan, Gastroenterologi dinominasikan dalam daftar Fudan.
-
The First Affiliated Hospital, Zhejiang University School of Medicine
Spesialisasi klinis kunci nasional
- Hematologi (tingkat A) http://zdygb.zju.edu.cn/2014/0106/c34026a1762975/page.htm
Juga diperingkat: Bedah Umum #7, Urologi #9, Penyakit Infeksi #2 dalam daftar Fudan.
-
Ruijin Hospital
Spesialisasi klinis kunci nasional
- Hematologi (tingkat B) https://www.rjh.com.cn/2018RJPortal/lcyxy2019/sy/jj/index.shtml
Juga diperingkat: Bedah Umum #4, Bedah Toraks #7 (seri), Pulmonologi #5 dalam daftar Fudan.
-
Beijing Hospital
Spesialisasi klinis kunci nasional
- Hematologi (tingkat B) https://www.bjhmoh.cn/index.php?id=4&r=archives/about&t=1790009033
Juga diperingkat: Urologi dinominasikan dalam daftar Fudan.
-
Peking University People's Hospital
Spesialisasi klinis kunci nasional
- Hematologi (tingkat B) https://www.pkuph.cn/news_details/26715.html
Juga diperingkat: Bedah Umum #10, Bedah Toraks #7, Ginekologi #7 dalam daftar Fudan.
-
Peking University Third Hospital
Spesialisasi klinis kunci nasional
- Hematologi (tingkat B) https://www.puh3.net.cn/yygk/zdxk.htm
Juga diperingkat: Ginekologi #4, Urologi dinominasikan, Gastroenterologi dinominasikan dalam daftar Fudan.
-
Anhui Provincial Hospital
Spesialisasi klinis kunci nasional
- Hematologi (tingkat B) https://www.ahslyy.com.cn/nanqu/col456/892156
Juga diperingkat: Bedah Umum dinominasikan, Otolaringologi dinominasikan dalam daftar Fudan.
Uji klinis (pengobatan dalam penelitian)
Selain perawatan standar, studi riset klinis untuk Leukaemia mungkin sedang terbuka bagi peserta di Tiongkok. Pengobatan yang diteliti belum disetujui regulator sebagai terapi standar — itu riset klinis, bukan perawatan rutin. Setiap catatan menyebutkan peneliti utama dan rumah sakit yang menjalankan studi itu. Bila Anda berminat, hubungi rumah sakit untuk menanyakan kelayakan dan tentukan sendiri apakah ingin mendaftar.
-
Studi The Efficacy and Safety of BCL-2 Inhibitors Combined with the HyperCVAD Regimen in the Treatment of Newly Diagnosed T-lymphoblastic Leukemia/ Lymphoma
- Peneliti utama
- Xianmin Song, MD · Investigator Official Title
- Rumah sakit
- Shanghai General Hospital
- Status
- Sedang merekrut
- Registri
- NCT06598722
-
Studi To Observe and Evaluate the Efficacy and Safety of Inaticabtagene Autoleucel Injection in the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia in Adults in the Real World
- Rumah sakit
- Peking University People's Hospital
- Status
- Sedang merekrut
- Registri
- NCT06450067
-
Studi A Clinical Study Evaluating the Safety and Efficacy of IL-15-armored Novel CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma and Plasma Cell Leukemia
- Peneliti utama
- FengYan Jin · Clinical Professor of Hematology Department
- Rumah sakit
- The First Hospital of Jilin University
- Status
- Sedang merekrut
- Registri
- NCT07509086
-
Studi Avapritinib Combined With Standard Therapy for the Treatment of Newly Diagnosed KIT Mutation Acute Myeloid Leukemia With t(8;21)(q22;q22.1); Inv(16)(p13.1q22) or t(16;16)(p13.1;q22): a Prospective, Multi-center, Single-arm, Two-cohorts Study
- Peneliti utama
- Chen Suning · Prof.
- Rumah sakit
- First Affiliated Hospital of Guangzhou Medical University
- Status
- Sedang merekrut
- Registri
- NCT07028073
-
Studi An Open-Label, Multi-Center, Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of YK012 in Participants With B-cell Acute Lymphoblastic Leukemia
- Rumah sakit
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University
- Status
- Sedang merekrut
- Registri
- NCT06580301
145 studi terdaftar lainnya
-
Studi A Phase IB Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Rumah sakit
- Peking University People's Hospital
- Status
- Sedang merekrut
- Registri
- NCT05091424
-
Studi Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in Pediatric Acute Myeloid Leukaemia: a Prospective Study
- Peneliti utama
- Chang Yingjun · Chief Physician
- Rumah sakit
- Peking University People's Hospital
- Status
- Sedang merekrut
- Registri
- NCT06452732
-
Studi Venetoclax-Azacitidine in Combination With Chidamide and CAG Versus 3+7 Regimen in Fit Older Patients With Acute Myeloid Leukaemia：A Multicenter, Randomized, Controlled, Phase 3 Trial
- Peneliti utama
- Daihong Liu · Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital
- Rumah sakit
- Chinese PLA General Hospital
- Status
- Sedang merekrut
- Registri
- NCT07514936
-
Studi A Multicenter, Prospective, Randomized Controlled Clinical Study Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in the Treatment of Adult Newly Diagnosed Early Precursor T-cell Acute Lymphoblastic Leukemia (ETP-ALL)
- Rumah sakit
- First Affiliated Hospital of Guangzhou Medical University
- Status
- Sedang merekrut
- Registri
- NCT06361329
-
Studi An Open-label, Clinical Study of CD7-targeted CAR-T Cells for the Treatment of Measurable Residual Disease of T-lymphoblastic Leukaemia/Lymphoma Post Allogeneic Stem Cell Transplantation
- Peneliti utama
- Xiao-Jun Huang · Chief
- Rumah sakit
- Peking University People's Hospital
- Status
- Sedang merekrut
- Registri
- NCT07280494
-
Studi A Multicenter Prospective Clinical Study of Inotuzumab Ozogamicin (INO) in the Treatment of Minimal Residual Disease Recurrent After Hematopoietic Stem Cell Transplantation of Acute Lymphoblastic Leukemia (ALL)
- Peneliti utama
- Sheng-Li Xue, MD · Professor
- Rumah sakit
- First Affiliated Hospital of Guangzhou Medical University
- Status
- Sedang merekrut
- Registri
- NCT05940961
-
Studi A Phase I/IIa, Open-Label Dose Escalation and Dose Expansion Study of Intravenous GFH009 Single Agent and in Combination With Venetoclax and Azacitidine in Patients With Relapsed/Refractory Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Rumah sakit
- First Affiliated Hospital of Guangzhou Medical University
- Status
- Sedang merekrut
- Registri
- NCT04588922
-
Studi MRD-positive AML: a Prospective, Single-arm, Multicenter Platform Clinical Study
- Rumah sakit
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
- Status
- Sedang merekrut
- Registri
- NCT07131059
-
Studi A Clinical Study on the Safety and Effectiveness of Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma
- Peneliti utama
- He Huang · Clinical Professor
- Rumah sakit
- First Affiliated Hospital of Guangzhou Medical University
- Status
- Sedang merekrut
- Registri
- NCT06633341
-
Studi Low-intensity Chemotherapy Combined With Targeted-Immunotherapy for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Prospective Clinical Cohort Study
- Rumah sakit
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
- Status
- Sedang merekrut
- Registri
- NCT07493161
-
Studi Clinical Study of CD5 Targeting Chimeric Antigen Receptor NK Cells (CAR-NK) in the Treatment of Relapse/Refractory T-Cell Hematologic Malignancies
- Rumah sakit
- Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
- Status
- Sedang merekrut
- Registri
- NCT06909474
-
Studi Open-label, Dose-escalation Phase 1 Clinical Study of SENL101 Autologous T Cell Injection in the Treatment of Adult Patients With Relapsed or Refractory T-LBL/ALL
- Rumah sakit
- Ruijin Hospital
- Status
- Sedang merekrut
- Registri
- NCT06136364
-
Studi A Multicenter, Single-Arm Clinical Study of the Venetoclax, Ivosidenib, and Azacitidine Triple-Drug Regimen in the Treatment of Chemotherapy-eligible Adult Patients With IDH1-Mutated Acute Myeloid Leukemia.
- Rumah sakit
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
- Status
- Sedang merekrut
- Registri
- NCT06611839
-
Studi The Safety and Efficacy for Anti-human CLL-1 CAR-NK Cells in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
- Peneliti utama
- Xianmin Song, MD · Doctor
- Rumah sakit
- Shanghai General Hospital
- Status
- Sedang merekrut
- Registri
- NCT06307054
-
Studi A Study of Chidamide With AZA in MRD Positive AML After Transplant
- Peneliti utama
- WENG Jian yu · professor
- Rumah sakit
- Guangdong Provincial People's Hospital
- Status
- Sedang merekrut
- Registri
- NCT06066905
-
Studi A Global Multicenter Open Label Randomized Phase III Confirmatory Study of Lisaftoclax (APG-2575) in Combination With Acalabrutinib vs Immunochemotherapy in Patients With Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
- Rumah sakit
- First Affiliated Hospital of Guangzhou Medical University
- Status
- Sedang merekrut
- Registri
- NCT06319456
-
Studi Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia
- Peneliti utama
- Siqi Li · Chief Technician
- Rumah sakit
- Peking University People's Hospital
- Status
- Sedang merekrut
- Registri
- NCT07537738
-
Studi A Single-arm, Open-label Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of U32 Injection in Patients With Acute Myeloid Leukemia.
- Rumah sakit
- First Affiliated Hospital of Guangzhou Medical University
- Status
- Sedang merekrut
- Registri
- NCT07036250
-
Studi Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia, a Prospective, Open, Multicenter, Randomized, Control Study (COMPLETE Study)
- Peneliti utama
- Xiao-Jun Huang · Prof.
- Rumah sakit
- Peking University People's Hospital
- Status
- Sedang merekrut
- Registri
- NCT06581081
-
Studi Clinical Study on the Safety and Efficacy of Autologous Hematopoietic Stem Cell Transplantation Combined With BCMA-CAR-T in the Treatment of Ultra-high Risk Multiple Myeloma
- Rumah sakit
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
- Status
- Sedang merekrut
- Registri
- NCT07109323
-
Studi Clinical Study Protocol to Evaluate the Safety and Efficacy of γδ T Cells for the Prevention of Relapse After Allogeneic Transplantation in Patients With High-risk Acute Myeloid Leukemia
- Peneliti utama
- Donghua Zhang · Director
- Rumah sakit
- Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
- Status
- Sedang merekrut
- Registri
- NCT07237230
-
Studi A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults
- Peneliti utama
- MEI HENG · Professor
- Rumah sakit
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Status
- Sedang merekrut
- Registri
- NCT07470073
-
Studi Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation in Comparison to Consolidation Therapy Based Venetoclax for Elderly Patients With Acute Myeloid Leukemia After First CR
- Peneliti utama
- He Huang · Discipline Leader of Bone Marrow Transplant Center
- Rumah sakit
- The First Affiliated Hospital, Zhejiang University School of Medicine
- Status
- Sedang merekrut
- Registri
- NCT06571825
-
Studi Study of the Efficacy and Safety of Venetoclax as Consolidation to Achieve Fix-Duration Treatment in CLL Patients Treated With BTK Inhibitor Monotherapy
- Rumah sakit
- Jiangsu Province Hospital
- Status
- Sedang merekrut
- Registri
- NCT06958705
-
Studi A Perspective, Multicenter, Open-label and Observational Trial for Unrelated Umbilical Cord Blood Stem Cell Microtransplantation Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and Secondary AML.
- Rumah sakit
- Jiangsu Province Hospital
- Status
- Sedang merekrut
- Registri
- NCT05584761
-
Studi The Efficacy and Safety of Homoharringtonine Combined With Venetoclax and Azacitidine Versus Standard Chemotherapy or VA in the Treatment of Acute Myeloid Leukemia With High-risk, a Multicenter, Prospective, Randomized Study
- Rumah sakit
- Nanfang Hospital
- Status
- Sedang merekrut
- Registri
- NCT06810791
-
Studi The Safety and Efficacy of CD19 & CD22 Bispecific CAR T Cells in Treating Relapsed / Refractory B Cell Hematological Tumors
- Peneliti utama
- MEI HENG · Proferssor, Cheif Doctor
- Rumah sakit
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Status
- Sedang merekrut
- Registri
- NCT06735495
-
Studi Haploidentical Hematopoietic Cell Transplantation Combined With an Unrelated Cord Blood Unit for Acute T Cell Lymphoblastic Leukemia Compared to Haploidentical Hematopoietic Cell Transplantation: a Multicenter, Randomized, Open-label Trial
- Rumah sakit
- First Affiliated Hospital of Guangzhou Medical University
- Status
- Sedang merekrut
- Registri
- NCT06381817
-
Studi A Prospective Cohort Study of a Pediatric-Inspired Chemotherapy Regimen Combined With Venetoclax and Immunotherapy for the Treatment of Adult Ph-Negative Acute Lymphoblastic Leukemia
- Rumah sakit
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
- Status
- Sedang merekrut
- Registri
- NCT07495631
-
Studi A Phase 1/2, Open-Label, Dose-Escalation and Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Chinese Patients With B-Cell Malignancies
- Rumah sakit
- First Affiliated Hospital of Guangzhou Medical University
- Status
- Sedang merekrut
- Registri
- NCT05294731
-
Studi A Randomized, Controlled, Prospective Study on the Efficacy and Safety of Active Immunity Induced by Autologous Peptides for Maintenance Therapy in Acute Myeloid Leukemia (AML)
- Peneliti utama
- HuangMeiJuan · Clinical Professor
- Rumah sakit
- Fujian Medical University Union Hospital
- Status
- Sedang merekrut
- Registri
- NCT07551037
-
Studi Assessment of the Safety and Efficacy of Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia: A Single-Arm, Open-Label, Prospective Study
- Rumah sakit
- First Affiliated Hospital of Guangzhou Medical University
- Status
- Sedang merekrut
- Registri
- NCT06696833
-
Studi A Multicenter, Open-label, Prospective, Randomized Controlled Study to Optimize the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease
- Peneliti utama
- Yehui Tan · Professor
- Rumah sakit
- The First Hospital of Jilin University
- Status
- Sedang merekrut
- Registri
- NCT07023588
-
Studi Reduced-dose Anti-thymocyte Globulin Plus Mini-dose Post-transplant Cyclophosphamide for GVHD Prevention in Haploidentical Donor HCT for Hematologic Malignancy
- Peneliti utama
- Xiao-Jun Huang · Peking University People's Hospital
- Rumah sakit
- Peking University People's Hospital
- Status
- Sedang merekrut
- Registri
- NCT06984536
-
Studi Exposure-Response and Prognostic Analysis of Venetoclax Therapeutic Drug Monitoring in Newly Diagnosed AML
- Peneliti utama
- CHEN Jia · Chief Physician of Hematology. Clinical Professor. Principal Investigator
- Rumah sakit
- First Affiliated Hospital of Guangzhou Medical University
- Status
- Sedang merekrut
- Registri
- NCT07670130
-
Studi Clinical Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
- Peneliti utama
- Chunyan Sun · Professor
- Rumah sakit
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Status
- Sedang merekrut
- Registri
- NCT06140966
-
Studi A Phase 3, Open-Label, Randomized, Multicenter Study to Evaluate Anti-tumor Efficacy of DZD8586 Versus Investigator's Choice in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Rumah sakit
- Jiangsu Province Hospital
- Status
- Sedang merekrut
- Registri
- NCT07139873
-
Studi Haploidentical Combined With Cord Blood Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes: A Prospective, Multicenter Clinical Study
- Rumah sakit
- Fujian Medical University Union Hospital
- Status
- Sedang merekrut
- Registri
- NCT07588360
-
Studi The Efficacy of Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia - a Prospective Phase Ⅱ Multicenter Clinical Trial From China
- Rumah sakit
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
- Status
- Sedang merekrut
- Registri
- NCT06530576
-
Studi A Phase I Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of APG-3288 in Patients With Relapsed/Refractory Hematological Malignancies
- Rumah sakit
- Henan Cancer Hospital
- Status
- Sedang merekrut
- Registri
- NCT07424833
-
Studi An Open-Label, Single-Arm, Phase II Exploratory Study of ABL and JAK Kinase Inhibitors With Chemotherapy and Venetoclax in Adult Patients With Ph-like ALL
- Rumah sakit
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
- Status
- Sedang merekrut
- Registri
- NCT07454226
-
Studi Cord Blood-derived CD70-targeting CAR-NK Cell Therapy for Refractory/Relapsed T Cell Lymphoma and Acute Myeloid Leukemia
- Rumah sakit
- The Second Affiliated Hospital Zhejiang University School of Medicine
- Status
- Sedang merekrut
- Registri
- NCT06696846
-
Studi HEC73543 Versus Salvage Chemotherapy in Relapsed or Refractory FLT3-ITD Acute Myeloid Leukemia: a Multicenter, Open-label, Randomized Phase 3 Trial
- Rumah sakit
- First Affiliated Hospital of Guangzhou Medical University
- Status
- Sedang merekrut
- Registri
- NCT05586074
-
Studi The Impact of Artificial Intelligence-Assisted Health Education on Patients' Intention to Participate in Clinical Trials: A Cluster-Randomised Controlled Trial
- Peneliti utama
- Fuling Zhou · Dean, School of Nursing, Wuhan University; Tenured Full Professor, Director of Department of Hematology, zhongnan Hospital,Wuhan University
- Rumah sakit
- Zhongnan Hospital of Wuhan University
- Status
- Sedang merekrut
- Registri
- NCT07305337
-
Studi The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk CEBPA Mutant Acute Myeloid Leukemia
- Peneliti utama
- Shen yang · Chief physician
- Rumah sakit
- Ruijin Hospital
- Status
- Sedang merekrut
- Registri
- NCT06458257
-
Studi A Multicenter, Open, Dose Escalation and Dose Expansion Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML)
- Rumah sakit
- First Affiliated Hospital of Guangzhou Medical University
- Status
- Sedang merekrut
- Registri
- NCT05947344
-
Studi A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia
- Rumah sakit
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
- Status
- Sedang merekrut
- Registri
- NCT07743112
-
Studi CD180 CART Cell Injection in the Treatment of Relapsed or Refractory CD180 Positive Hematologic Malignancies: a Prospective, Single-arm, Single-center Clinical Study.
- Rumah sakit
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
- Status
- Sedang merekrut
- Registri
- NCT07106749
-
Studi Phase I Clinical Trial Protocol for Tolerability and Pharmacokinetics of TQB3455 Tablets in Patients With Hematological Malignancies
- Rumah sakit
- Peking University People's Hospital
- Status
- Sedang merekrut
- Registri
- NCT06550713
-
Studi To Evaluate Safety and Efficiency of AZA Combined With Chidamide as Maintenance Therapy in High-risk Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation：A Multicenter, Single-arm Study
- Rumah sakit
- Nanfang Hospital
- Status
- Sedang merekrut
- Registri
- NCT05270200
-
Studi A Prospective,Randomized,and Comparative Study on the Efficacy of Venetoclax Combined With CACAG Regimen and BAT Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
- Peneliti utama
- Daihong Liu · doctor
- Rumah sakit
- Chinese PLA General Hospital
- Status
- Sedang merekrut
- Registri
- NCT06084819
-
Studi A Phase 2, Multicenter, Single-arm, Open-label Study on the Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic Leukemia
- Rumah sakit
- Anhui Provincial Hospital
- Status
- Sedang merekrut
- Registri
- NCT06224257
-
Studi A Phase I Clinical Study on the Safety, Tolerability, and Efficacy of KSV01 Injection in Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
- Peneliti utama
- He Huang · Clinical Professor
- Rumah sakit
- The First Affiliated Hospital, Zhejiang University School of Medicine
- Status
- Sedang merekrut
- Registri
- NCT07246707
-
Studi An Open-label, Multi-center, Phase I Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IBR733 Cell Injection in Acute Myeloid Leukemia
- Rumah sakit
- First Affiliated Hospital of Guangzhou Medical University
- Status
- Sedang merekrut
- Registri
- NCT06234904
-
Studi An Exploratory Study on Targeted CD22/CD19 Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy for Enhanced Consolidation Therapy of Standard-risk B-cell Acute Lymphoblastic Leukemia
- Peneliti utama
- Liping Dou · Director
- Rumah sakit
- Chinese PLA General Hospital
- Status
- Sedang merekrut
- Registri
- NCT07575919
-
Studi Multicenter, Randomized Controlled Clinical Study on Early Application of Realgar-Indigo Naturalis Formula (RIF) for Treatment of Acute Promyelocytic Leukemia (APL)
- Rumah sakit
- The First Affiliated Hospital of Xi'an Jiaotong University
- Status
- Sedang merekrut
- Registri
- NCT07503730
-
Studi Effectiveness and Safety of Blinatumomab and Donor Lymphocyte Infusion in Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Ph Negative B Cell Acute Lymphoblastic Leukemia：Phrase II, Exploratory Study
- Rumah sakit
- The First Affiliated Hospital, Zhejiang University School of Medicine
- Status
- Sedang merekrut
- Registri
- NCT07105579
-
Studi Clinical Trial for the Safety and Efficacy of CAR-T Cells Therapy for Patients With the Central Nervous System Involvement of Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia or B-cell Non-Hodgkin's Lymphoma
- Peneliti utama
- He Huang · Clinical Professor
- Rumah sakit
- First Affiliated Hospital of Guangzhou Medical University
- Status
- Sedang merekrut
- Registri
- NCT04532203
-
Studi PA3-17 Injection for the Treatment of Subjects With Relapsed/Refractory T-Lymphoblastic Leukemia/Lymphoma: A Single-Arm, Open-Label Phase II Clinical Trial
- Rumah sakit
- First Affiliated Hospital of Guangzhou Medical University
- Status
- Sedang merekrut
- Registri
- NCT07188610
-
Studi A Phase I Dose-Escalation and Phase II Study of Nanobody-Based CD19/CD22 Tandem Dual Chimeric Antigen Receptor (CAR) T-cell Therapy in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
- Peneliti utama
- Xiao-Jun Huang · Director of Peking University Institute of Hematology
- Rumah sakit
- Peking University People's Hospital
- Status
- Sedang merekrut
- Registri
- NCT06880913
-
Studi Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for Relapsed/refractory Acute Myeloid Leukemia
- Peneliti utama
- Xiao-Ning Gao · Chief Physician
- Rumah sakit
- Chinese PLA General Hospital
- Status
- Sedang merekrut
- Registri
- NCT06741722
-
Studi A Phase 1, Open-label, Multicentre Study Evaluating the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics, and Preliminary Efficacy of CG009301 for Injection in Adult Subjects With Relapsed or Refractory Haematological Malignancies
- Rumah sakit
- The First Affiliated Hospital of Nanchang University
- Status
- Sedang merekrut
- Registri
- NCT07347171
-
Studi A Phase I/II Single-center Study Evaluating the Safety and Efficacy of BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in Adults With Refractory/Relapsed B-cell Acute Lymphoblastic Leukaemia
- Peneliti utama
- Han weidong · Director of Biotherapeutic Department
- Rumah sakit
- First Hospital of China Medical University
- Status
- Sedang merekrut
- Registri
- NCT07008885
-
Studi A Prospective, Multicenter Clinical Study on The Safety and Efficacy of Avapritinib in The Treatment of Relapsed/Refractory Pediatric Core Binding Factor Acute Myeloid Leukemia (CBF-AML) With KIT Mutation
- Peneliti utama
- Shaoyan Hu · Study Chair
- Rumah sakit
- Anhui Provincial Hospital
- Status
- Sedang merekrut
- Registri
- NCT06316960
-
Studi The Efficacy and Safety of Third Generation Tyrosine Kinase Inhibitors Combined With Azacitidine and B-cell Lymphoma-2 Inhibitor in Patients With Myeloid Blast Phase Chronic Myeloid Leukemia
- Peneliti utama
- Qian Jiang · Professor
- Rumah sakit
- Peking University People's Hospital
- Status
- Sedang merekrut
- Registri
- NCT06390306
-
Studi The Safety and Efficay Investigation of IL-5 CAR-T Cell Therapy for Patients With Refractory/Relapsed Eosinophilic Leukemia
- Peneliti utama
- He Huang · Clinical Professor
- Rumah sakit
- First Affiliated Hospital of Guangzhou Medical University
- Status
- Sedang merekrut
- Registri
- NCT07257640
-
Studi The Efficacy and Safety of VA Alternating With Low-dose CHA in the Treatment of Newly Diagnosed Unfit AML: a Prospective, Multi-centers, Single Arm Phase II Study
- Peneliti utama
- Jie Sun · Principle Attending, Associated Professor
- Rumah sakit
- Beijing Chao-Yang Hospital, Capital Medical University
- Status
- Sedang merekrut
- Registri
- NCT07172204
-
Studi An Exploratory Clinical Study of CAR-T Cell Immunotherapy Using Polymer-lipid Particles to Deliver CAR1920 mRNA Targeting CD19/CD20 for Thetreatment of Relapsed/Refractory B-cell Lymphoma/Leukemia
- Peneliti utama
- Daihong Liu · Dr.
- Rumah sakit
- Chinese PLA General Hospital
- Status
- Sedang merekrut
- Registri
- NCT07321301
-
Studi Blinatumomab Sequential Donor Lymphocyte Infusion in Acute B Lymphocytic Leukemia Observation of Therapeutic Effect in Patients With Recurrence After Allogeneic Hematopoietic Stem Cell Transplantation
- Peneliti utama
- Suping ZHANG · visiting staff
- Rumah sakit
- First Affiliated Hospital of Zhengzhou University
- Status
- Sedang merekrut
- Registri
- NCT06339775
-
Studi A Preliminary Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetic Profile of KQ-2002 (CD19/CD22 CAR-T) in Adults With Recurrent or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
- Peneliti utama
- Rong Tao · Chief physician
- Rumah sakit
- The First Affiliated Hospital of Nanchang University
- Status
- Sedang merekrut
- Registri
- NCT06445803
-
Studi Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies
- Rumah sakit
- First Affiliated Hospital of Guangzhou Medical University
- Status
- Sedang merekrut
- Registri
- NCT07284927
-
Studi A Phase Ib/II, Open-Label, Dose-Escalation and Cohort Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of PBSS1113 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Rumah sakit
- The First Affiliated Hospital, Zhejiang University School of Medicine
- Status
- Sedang merekrut
- Registri
- NCT07761533
-
Studi A Phase 1 Study of ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies.
- Rumah sakit
- Anhui Provincial Hospital
- Status
- Sedang merekrut
- Registri
- NCT06656494
-
Studi Dose Escalation Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Decitabine and Cytarabine (D-CMG) for the Treatment of Elderly Newly Diagnosed Acute Myeloid Leukemia (AML) Patients
- Peneliti utama
- Bing, Xu · Principal Investigator
- Rumah sakit
- First Affiliated Hospital of Guangzhou Medical University
- Status
- Sedang merekrut
- Registri
- NCT06651866
-
Studi The First Affiliated Hospital, Zhejiang University School of Medicine
- Peneliti utama
- He Huang · The President of the First Affiliated Hospital, Zhejiang University School of Medicine
- Rumah sakit
- First Affiliated Hospital of Guangzhou Medical University
- Status
- Sedang merekrut
- Registri
- NCT06076226
-
Studi The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk Core-binding-factor Acute Myeloid Leukemia
- Peneliti utama
- Shen yang · Chief physician
- Rumah sakit
- Ruijin Hospital
- Status
- Sedang merekrut
- Registri
- NCT06458244
-
Studi A Multicenter, Single-Arm, Prospective Clinical Study of Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia
- Peneliti utama
- Xiao-Jun Huang · Prof.
- Rumah sakit
- Peking University People's Hospital
- Status
- Sedang merekrut
- Registri
- NCT06869265
-
Studi An Early Exploratory Clinical Study of the Safety, Tolerability and Preliminary Efficacy of JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma/Leukaemia
- Peneliti utama
- Jia Wei · professor
- Rumah sakit
- Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
- Status
- Sedang merekrut
- Registri
- NCT06689917
-
Studi An Exploratory Study on the Safety and Efficacy of Luspatercept in the Treatment of Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia
- Peneliti utama
- Liang Zhao · Professor
- Rumah sakit
- Zhujiang Hospital of Southern Medical University
- Status
- Sedang merekrut
- Registri
- NCT07362095
-
Studi A Single-arm, Prospective Study of a Cladribine-Bridged Lisaftolax and Busulfan Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia in Elderly Patients
- Rumah sakit
- First Affiliated Hospital of Guangzhou Medical University
- Status
- Sedang merekrut
- Registri
- NCT07500753
-
Studi A Prospective, Multicenter, and Exploratory Study of Mitoxantrone Liposomes, Cytarabine and G-CSF Combined With Vineclavone in the Treatment ofRecurrent Adult AML and MDS-EB-2/Elder AML
- Rumah sakit
- Ruijin Hospital
- Status
- Sedang merekrut
- Registri
- NCT06329999
-
Studi Prospective Randomized Study of the Effectiveness and Safety of Chemotherapy Protocols Containing Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3)
- Peneliti utama
- HuangMeiJuan · Chief Physician
- Rumah sakit
- Fujian Medical University Union Hospital
- Status
- Sedang merekrut
- Registri
- NCT07561892
-
Studi Predicting Patient Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: A Comparison of Measurable Residual Disease (MRD) Assessment by Digital Polymerase Chain Reaction and Conventional MRD
- Peneliti utama
- Xiao-Jun Huang · Professor
- Rumah sakit
- Peking University People's Hospital
- Status
- Sedang merekrut
- Registri
- NCT06211166
-
Studi A Single-Arm, Multicenter, Open-Label, Dose- Escalating and Expanding,Phase I/II Study of SKLB1028 Combined With "7+3" Standard Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Rumah sakit
- West China Hospital, Sichuan University
- Status
- Sedang merekrut
- Registri
- NCT05445154
-
Studi Study on the Efficacy and Safety of VMAC Combined With Donor Lymphocyte Infusion (DLI) in the Treatment of Patients With Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation
- Rumah sakit
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
- Status
- Sedang merekrut
- Registri
- NCT06447090
-
Studi A Multi-center Prospective Single Arm Clinical Study of Prolonged Ultra Low-dose Decitabine Combined With Venetoclax (Bcl-2 Inhibitor) as First Line Treatment for Elderly Acute Myeloid Leukemia and High-risk Myelodysplastic Syndromes
- Peneliti utama
- Weiyan Zheng · Clinical Professor
- Rumah sakit
- First Affiliated Hospital of Guangzhou Medical University
- Status
- Sedang merekrut
- Registri
- NCT06046313
-
Studi Super-universal CD7 CART (supCD7 CART) Cell Injection in the Treatment of Relapsed or Refractory CD7 Positive Hematologic Malignancies: a Prospective, Single-arm, Single-center Clinical Study.
- Rumah sakit
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
- Status
- Sedang merekrut
- Registri
- NCT07153068
-
Studi A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haploidentical Hematopoietic Stem Cell Transplantation Using a TBI or TMLI Conditioning Regimen for Pediatric Acute Lymphoblastic Leukemia
- Peneliti utama
- Xiangbo Wan · Professor
- Rumah sakit
- First Affiliated Hospital of Zhengzhou University
- Status
- Sedang merekrut
- Registri
- NCT06559345
-
Studi The Significance of Serum Ferritin in the Diagnosis, Differential Diagnosis, and Prognosis of Immune-related Adverse Event (irAE)
- Rumah sakit
- Tianjin Medical University Cancer Institute & Hospital
- Status
- Sedang merekrut
- Registri
- NCT06702566
-
Studi Safety and Efficacy of Universal Off-the-shelf CAR-NK Cells Targeted CD123 (JD123 Injection) in the Treatment of Refractory or Relapsed CD123-positive Acute Myeloid Leukemia
- Peneliti utama
- Xiao-Jun Huang · Professor
- Rumah sakit
- Peking University People's Hospital
- Status
- Sedang merekrut
- Registri
- NCT06201247
-
Studi Exploratory Clinical Study of JAK1 Inhibitor Golidocitnib in the Treatment of Relapsed/Refractory Indolent T/NK-Cell Lymphomas：An Open, Prospective, Exploratory Clinical Trial
- Rumah sakit
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
- Status
- Sedang merekrut
- Registri
- NCT06716658
-
Studi A Single-Center, Prospective, Single-Arm Phase II Clinical Study of Consolidation With High-Dose Cytarabine Following Deep Molecular Remission Induced by Gilteritinib Plus VA Regimen in Newly Diagnosed Intermediate-Risk Fit AML Patients With FLT3-ITD Mutation
- Peneliti utama
- Jie Sun · Principle Attending, Associated Professor
- Rumah sakit
- The First Affiliated Hospital, Zhejiang University School of Medicine
- Status
- Sedang merekrut
- Registri
- NCT07259707
-
Studi A Clinical Study of Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for B-Cell Acute Lymphoblastic Leukemia(B-ALL) Patients in First Complete Remission (CR1)，Minimal Residual Disease(MRD) Positive
- Peneliti utama
- Jin Wang · chief physician, MD, PhD
- Rumah sakit
- Ruijin Hospital
- Status
- Sedang merekrut
- Registri
- NCT06718244
-
Studi Donor Derived CD117 CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
- Peneliti utama
- He Huang · Principal Investigator
- Rumah sakit
- First Affiliated Hospital of Guangzhou Medical University
- Status
- Sedang merekrut
- Registri
- NCT07144020
-
Studi CD123-Targeted CD16 Antibody-Modified NK Cell Immunotherapy for Refractory/Relapsed Acute Myeloid Leukemia (R/R AML)
- Peneliti utama
- Chunji Gao · Principal Investigator
- Rumah sakit
- Chinese PLA General Hospital
- Status
- Sedang merekrut
- Registri
- NCT06835140
-
Studi A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
- Rumah sakit
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
- Status
- Sedang merekrut
- Registri
- NCT06880354
-
Studi CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia: a Prospective, Single-arm, Single-center, Phase 2 Clinical Trial
- Peneliti utama
- LIANG WANG · Director of the department of hematology
- Rumah sakit
- Beijing Tongren Hospital
- Status
- Sedang merekrut
- Registri
- NCT06081478
-
Studi Prospective, Multicenter, Real-world Study of Dolasetron Mesylate Injection for the Prevention of Chemotherapy-induced Nausea and Vomiting in Children With Acute Lymphoblastic Leukemia
- Peneliti utama
- Tianping Chen · Associate chief physician
- Rumah sakit
- Anhui Provincial Children's Hospital
- Status
- Sedang merekrut
- Registri
- NCT06756022
-
Studi A Phase II/III Study of ICP-248 in Combination With Orelabrutinib in Patients With Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Rumah sakit
- First Affiliated Hospital of Guangzhou Medical University
- Status
- Sedang merekrut
- Registri
- NCT06378138
-
Studi Tracjectories and Predictors of Chemotherapy Induced Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia: A Perspective Longitudinal Study
- Peneliti utama
- Dr Eva Ho · Associate professor
- Rumah sakit
- Henan Cancer Hospital
- Status
- Sedang merekrut
- Registri
- NCT07326930
-
Studi A Multicenter, Randomized, Open-Label, Phase III Clinical Study to Evaluate the Efficacy and Safety of HMPL-306 vs. Salvage Chemotherapy Regimens in Patients With IDH1- and IDH2-mutated Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
- Rumah sakit
- First Affiliated Hospital of Guangzhou Medical University
- Status
- Sedang merekrut
- Registri
- NCT06387069
-
Studi A Multicenter, Prospective, Single-Arm Study of Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Peneliti utama
- Bing, Xu · Dr. Bing Xu
- Rumah sakit
- First Affiliated Hospital of Guangzhou Medical University
- Status
- Sedang merekrut
- Registri
- NCT07783100
-
Studi A Clinical Study to Explore the Safety, Efficacy, and Pharmacokinetics of CT0596 CAR-T Cell Injection in Patients With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia
- Status
- Sedang merekrut
- Registri
- NCT06718270
-
Studi Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia
- Peneliti utama
- Shuhong Shen · Chair of hematology oncology department of SCMC
- Rumah sakit
- Anhui Provincial Children's Hospital
- Status
- Sedang merekrut
- Registri
- NCT06607419
-
Studi A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
- Rumah sakit
- Peking University People's Hospital
- Status
- Sedang merekrut
- Registri
- NCT06927466
-
Studi Safety and Efficacy Study of Demethylating Agents With Venetoclax in Preventing Recurrence of High-risk T-cell Lymphoblastic Lymphoma/Leukemia After Transplantation
- Peneliti utama
- Xianmin Song, MD · Professor
- Rumah sakit
- Shanghai General Hospital
- Status
- Sedang merekrut
- Registri
- NCT06686108
-
Studi A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Rumah sakit
- Peking Union Medical College Hospital
- Status
- Sedang merekrut
- Registri
- NCT06973187
-
Studi A Randomized, Controlled, Double-Blind, Multicenter, Phase Ⅲ Study to Evaluate the Efficacy and Safety of IMM01 (Timdarpacept) in Combination With Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)
- Rumah sakit
- Anhui Provincial Hospital
- Status
- Sedang merekrut
- Registri
- NCT06647862
-
Studi Clinical Study on the Safety and Efficacy of CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.
- Rumah sakit
- Guangzhou Women and Children's Medical Center
- Status
- Sedang merekrut
- Registri
- NCT06752785
-
Studi The Safety and Efficacy of RD06-03 CART Cell Injection in Patients With Relapsed or Refractory B-lymphoblastic Leukemia
- Peneliti utama
- Xiaoyu Zhu · Chief Prof.
- Rumah sakit
- Anhui Provincial Hospital
- Status
- Sedang merekrut
- Registri
- NCT06307600
-
Studi A Single-center, Single-arm, Prospective Clinical Study of Intermediate-dose Cytarabine in Combination With Venetoclax for Consolidation Therapy of Middle- and High-risk Acute Myeloid Leukemia in The Elderly
- Peneliti utama
- Yehui Tan · Professor
- Rumah sakit
- The First Hospital of Jilin University
- Status
- Sedang merekrut
- Registri
- NCT06990321
-
Studi Phase 2 Trial of Menin Inhibitor BN104 as Post Hematopoietic Stem Cell Transplantation Maintenance in Patients With Acute Leukemia
- Peneliti utama
- Chen Suning · Prof.
- Rumah sakit
- First Affiliated Hospital of Guangzhou Medical University
- Status
- Sedang merekrut
- Registri
- NCT07101497
-
Studi A Prospective, Randomized Controlled Clinical Study on the Efficacy and Safety of the TmBU Regimen Versus mBUCY Regimen for Conditioning Before Allo-HSCT in High-risk or Relapsed/Refractory Acute Leukemia
- Peneliti utama
- Sheng-Li Xue, MD · Prof.
- Rumah sakit
- First Affiliated Hospital of Guangzhou Medical University
- Status
- Sedang merekrut
- Registri
- NCT06816134
-
Studi A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BL-M11D1 in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients
- Rumah sakit
- Anhui Provincial Hospital
- Status
- Sedang merekrut
- Registri
- NCT05924750
-
Studi Prospective Single-Arm Clinical Study of Thiotepa-Containing Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia
- Peneliti utama
- Sun Yuqian · Principal Investigator
- Rumah sakit
- Peking University People's Hospital
- Status
- Sedang merekrut
- Registri
- NCT07588594
-
Studi A Novel Post-transplant Regimen of PT/FLU+CY for Selectively Promoting Unrelated Cord Blood Engraftment in Haploidentical-cord Transplantation in Childhood Leukemia: a Single-arm, Multi-center Trial
- Rumah sakit
- Nanfang Hospital
- Status
- Sedang merekrut
- Registri
- NCT06155188
-
Studi A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)
- Rumah sakit
- Second Xiangya Hospital of Central South University
- Status
- Sedang merekrut
- Registri
- NCT05254743
-
Studi A Single-arm, Dose-escalation and Dose-expansion Phase I Clinical Study to Evaluate the Tolerability, Safety and Preliminary Efficacy of BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
- Rumah sakit
- Zhujiang Hospital of Southern Medical University
- Status
- Sedang merekrut
- Registri
- NCT06118788
-
Studi A Prospective, Multicenter, Randomized Controlled Study on the MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
- Rumah sakit
- First Affiliated Hospital of Zhengzhou University
- Status
- Sedang merekrut
- Registri
- NCT06345365
-
Studi A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Rumah sakit
- China-Japan Friendship Hospital
- Status
- Sedang merekrut
- Registri
- NCT06943872
-
Studi A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations Who Are Ineligible for Intensive Chemotherapy
- Rumah sakit
- Peking University First Hospital
- Status
- Sedang merekrut
- Registri
- NCT06852222
-
Studi A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Rumah sakit
- Shenzhen People's Hospital
- Status
- Belum merekrut
- Registri
- NCT07676006
-
Studi Clinical Study on the Safety and Efficacy of QH101 in Patients With Relapsed/Refractory Acute Myeloid Leukemia(R/R AML) and Relapsed/Refractory Myelodysplastic Syndromes(R/R MDS)
- Peneliti utama
- Xiaoyu Zhu · Director of Hematology Department
- Rumah sakit
- Anhui Provincial Hospital
- Status
- Belum merekrut
- Registri
- NCT07131085
-
Studi A Multicenter, Prospective Clinical Study of Olverembatinib Combined With Blinatumomab in the Treatment of Adult de Novo Philadelphia Chromosome Positive Acute Lymphoid Leukemia
- Peneliti utama
- Chen Suning · Principal Investigator
- Rumah sakit
- First Affiliated Hospital of Soochow University
- Status
- Belum merekrut
- Registri
- NCT05931757
-
Studi Single-Arm, Multicenter, Prospective Phase II Clinical Study of Rituximab Combined With Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for Richter Syndrome Transformed From Chronic Lymphocytic Leukemia
- Rumah sakit
- Henan Cancer Hospital
- Status
- Belum merekrut
- Registri
- NCT07831395
-
Studi Comparing the Efficacy and Safety of Decitabine-Fludarabine-busulfan (Dec-FB4) and Fludarabine-busulfan (FB4) as Conditioning Regimens for AML-MR
- Peneliti utama
- Hu Xiaoxia · Principal Investigator
- Rumah sakit
- Ruijin Hospital
- Status
- Belum merekrut
- Registri
- NCT06297772
-
Studi A Prospective, Multicenter, Randomized Controlled, Open Label, Non-Inferiority Study Comparing the Efficacy and Safety of the VA Regimen (Venetoclax Combined With Azacitidine) With the "3+7" Regimen in the Treatment of Newly Diagnosed AML Patients With NPM1 or IDH1/IDH2 Mutations
- Peneliti utama
- Shen yang · Chief Physician, Professor, Department of Hematology
- Rumah sakit
- Ruijin Hospital
- Status
- Belum merekrut
- Registri
- NCT07664839
-
Studi A Phase 1b/2 Study of AK117 (Anti-CD47 Antibody) in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia
- Rumah sakit
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
- Status
- Belum merekrut
- Registri
- NCT06387420
-
Studi A Clinical Study to Investigate the Safety and Efficacy of CT0991 in Patients With Relapsed/Refractory Acute Myeloid Leukemia.
- Peneliti utama
- MEI HENG · Principal Investigator
- Rumah sakit
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Status
- Belum merekrut
- Registri
- NCT07233018
-
Studi Effectiveness and Safety of Inotuzumab Ozogamicin±Donor Lymphocyte Infusion for Relapsed B Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma After Allogeneic Hematopoietic Stem Cell Transplantation：Phrase II, Multicenter Study
- Peneliti utama
- Yi Luo · Clinical Professor
- Rumah sakit
- First Affiliated Hospital of Guangzhou Medical University
- Status
- Belum merekrut
- Registri
- NCT06861348
-
Studi A Prospective, Multicenter, Open-label, Randomized Controlled Trial of SHR2554 Plus Azacitidine in Overlapped Sequential Combination With Modified BUCY Conditioning Regimen in Patients With High-risk or Relapsed/Refractory Acute Leukemia and Myelodysplastic Neoplasms Secondary IDs
- Peneliti utama
- Limin Liu,MD · Principal Investigator
- Rumah sakit
- First Affiliated Hospital of Guangzhou Medical University
- Status
- Belum merekrut
- Registri
- NCT07575412
-
Studi Safety and Efficacy of CLL1 CAR-T Followed by Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
- Peneliti utama
- Donghua Zhang · professor
- Rumah sakit
- Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
- Status
- Belum merekrut
- Registri
- NCT07342244
-
Studi Assessment of the Safety and Efficacy of Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia: A Single-Arm, Open-Label, Prospective Study
- Rumah sakit
- First Affiliated Hospital of Guangzhou Medical University
- Status
- Belum merekrut
- Registri
- NCT06559644
-
Studi An Early Exploratory Clinical Study on the Safety, Tolerability, and Preliminary Efficacy of JY231 Injection in the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Peneliti utama
- He Huang · Professor, Director of the Bone Marrow Transplantation Center
- Rumah sakit
- The First Affiliated Hospital, Zhejiang University School of Medicine
- Status
- Belum merekrut
- Registri
- NCT06902025
-
Studi Phase I Clinical Study of CD19-targeting Chimeric Antigen Receptor T Lymphocyte (MC-1-50) for the Treatment of Relapsed/Refractory CD19-positive B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Rumah sakit
- Ruijin Hospital
- Status
- Belum merekrut
- Registri
- NCT06641024
-
Studi A Multicenter Prospective Study on Structuralized Follow-up Model Construction and Late Effect Burden of Childhood Hematological Malignancy Survivors (HEM-SURVIVE)
- Peneliti utama
- zhangjingying · Principal Investigator
- Rumah sakit
- Children's Hospital Zhejiang University School of Medicine
- Status
- Belum merekrut
- Registri
- NCT07483749
-
Studi A Single-Arm, Prospective Clinical Study of the Efficacy and Safety of VABu Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Non-High-Risk AML Patients in CR1 With Low Performance Status (ECOG ≥ 2) or High Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI ≥ 2)
- Rumah sakit
- First Affiliated Hospital of Soochow University
- Status
- Belum merekrut
- Registri
- NCT07762508
-
Studi An Exploratory Clinical Study Evaluating the Safety and Pharmacokinetic Profile of SNC116 in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
- Rumah sakit
- The First Hospital of Jilin University
- Status
- Belum merekrut
- Registri
- NCT07830238
-
Studi A Multicenter, Open-Label, Phase 1/2 Clinical Study of the Safety and Efficacy of Aclarubicin Combined With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia
- Peneliti utama
- Junmin Li · Chief Physician of hematology
- Rumah sakit
- Ruijin Hospital
- Status
- Belum merekrut
- Registri
- NCT07486726
-
Studi Efficacy and Safety of Maintenance Treatment With Chidamide, Venetoclax, and Azacitidine for Treatment-Naive Acute Myeloid Leukemia Patients Achieving Complete Remission: A Multicenter Study
- Rumah sakit
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Status
- Belum merekrut
- Registri
- NCT07521124
-
Studi A Multicenter, Open, Single-arm Phase I Dose-escalation and Dose-expansion Clinical Study: Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of FXS0683 Tablets in Patients With Relapsed or Refractory Hematologic Malignancies.
- Rumah sakit
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College
- Status
- Belum merekrut
- Registri
- NCT07616089
-
Studi A Prospective Study on the Efficacy and Safety of Venetoclax, Azacitidine, and Homoharringtonine (VAH) Combination as a Bridging Regimen to Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Acute Myeloid Leukemia
- Rumah sakit
- Ruijin Hospital
- Status
- Belum merekrut
- Registri
- NCT07091006
-
Studi Efficacy and Safety of Zanubrutinib, Obinutuzumab, and Bendamustine (ZGB) Regimen for First-Line Treatment of Chronic Lymphocytic Leukemia: A Single-Arm, Prospective Study
- Peneliti utama
- Ou Bai, MD/PHD · Director
- Rumah sakit
- The First Hospital of Jilin University
- Status
- Belum merekrut
- Registri
- NCT07003464
-
Studi A Prospective, Open-Label, Single-Arm, Two-Cohort Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Bcl-2 Inhibitor Combined With Azacitidine in the Treatment of Newly Diagnosed Mixed Phenotype Acute Leukemia
- Peneliti utama
- Chen Suning · Doctor
- Rumah sakit
- First Affiliated Hospital of Guangzhou Medical University
- Status
- Belum merekrut
- Registri
- NCT07573670
-
Studi This is a Multicenter, Retrospective Real-world Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China
- Peneliti utama
- Xiao-Jun Huang · Prof.
- Rumah sakit
- Peking University People's Hospital
- Status
- Belum merekrut
- Registri
- NCT06557304
Halaman ini hanya membagikan informasi studi yang terdaftar secara publik. Halaman ini tidak menganjurkan atau mendorong keikutsertaan dalam studi mana pun. Keikutsertaan sepenuhnya sukarela dan risiko pengobatan yang belum disetujui tidak diketahui; hubungi rumah sakit langsung untuk kelayakan dan rincian persetujuan setelah penjelasan.
Terapi lanjutan: apa yang sudah berizin dan apa yang masih dalam uji klinis
Rumah sakit dengan catatan spesialisasi kunci nasional
Tampilkan catatan rumah sakit 21 rumah sakit dengan catatan spesialisasi kunci
Setiap baris adalah rumah sakit dengan catatan spesialisasi klinis kunci nasional pada spesialisasi tempat penyakit ini dikelompokkan. Ini catatan daftar terbit, bukan rekomendasi dan bukan peringkat.
21 rumah sakit dengan catatan spesialisasi kunci nasional yang cocok.
Nilai yang ditulis dalam bahasa Tiongkok dikutip sebagaimana diterbitkan oleh sumber.
Apa yang dilaporkan pasien
Hanya angka agregat: hasil nasional yang dikutip dengan sumbernya dan tahun yang dirujuknya. Ini bukan testimoni pasien dan bukan pernyataan tentang satu orang.
Sebagaimana dilaporkan dalam National Health Commission - 2023 national tertiary public hospital performance monitoring circular (国卫医政函〔2025〕55 号) (2023): National inpatient satisfaction / outpatient satisfaction — 95.42 / 93.95 score, 0-100.
National aggregate across the 2,168 tertiary public hospitals that took part in the national performance monitoring (all conditions combined; not disease-specific, not hospital-specific).
Sumber: National Health Commission - 2023 national tertiary public hospital performance monitoring circular (国卫医政函〔2025〕55 号) — https://www.gov.cn/zhengce/zhengceku/202503/content_7016208.htm — 2023 — Tingkat A
Pertanyaan tentang penyakit ini
Kami tidak dapat memberikan nasihat medis, tetapi kami dapat menjawab pertanyaan tentang halaman ini dan tentang mengatur pengobatan di Tiongkok.
Kode ICD
Tampilkan tabel kode 5 kode ICD
| Versi | Kode | Nama dalam versi itu |
|---|---|---|
| ICD-10-WHO | C91 | Lymphoid leukaemia |
| ICD-10-WHO | C92 | Myeloid leukaemia |
| ICD-10-WHO | C93 | Monocytic leukaemia |
| ICD-10-WHO | C94 | Other leukaemias of specified cell type |
| ICD-10-WHO | C95 | Leukaemia of unspecified cell type |
Baris-barisnya adalah entri ICD-10 WHO untuk penyakit ini, dikutip sebagaimana diterbitkan.
Sumber & bukti
- URL sumber
- https://www3.ha.org.hk/cancereg/tc/icd10.html
- Skema sumber
- https
- Jenis sumber
- Kompilasi pihak ketiga
- Tingkat bukti
- A - dinyatakan oleh komisi kesehatan, lembaga riset nasional, atau universitas
- Diambil pada
- 2026-10-01